|
| Issue Date | Title | Author(s) | Type | Cat. |
| 2020 | Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ) | Ziemssen, T.; Bass, A. D.; Berkovich, R.; Eichau, S.; Hobart, J.; Hunter, S. F.; Limmroth, V.; Pelletier, D.; Pozzilli, C.; Schippling, S.; Singer, B. A.; Sousa, L.; Traboulsee, A.; Uittlehaag, B. M. J.; VAN WIJMEERSCH, Bart ; Poole, E. M.; Choudhry, Z.; Geertsen, S.; Daizadeh, N.; Comi, G. | Journal Contribution | M |
| 2018 | Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE | Hupperts, R.; Hobart, J.; Gasperini, C.; Lycke, J.; Ziemssen, T.; FEYS, Peter ; McNeill, M.; Acosta, C.; Meergans, M. | Journal Contribution | M |
| 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart ; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre ; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 2017 | Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study | Hobart, J.; Ziemssen, T.; FEYS, Peter ; Linnebank, M.; Goodman, A.; Farrell, R.; Hupperts, R.; Englishby, V.; McNeill, M.; Chang, I.; Lima, G. | Journal Contribution | M |
| 2016 | Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study. | Hobart, Jeremy; Ziemssen, T.; FEYS, Peter ; Linnebank, M.; Goodman, A.; Farrell, R.; Englishby, V.; McNeill, M.; Chang, I.; Mehta, L.; Elkins, J. | Journal Contribution | M |
| 2015 | Long-term efficacy and safety of prolonged-release fampridine treatment in patients with multiple sclerosis: design of the multicentre, randomised, double-blind, placebo-controlled ENHANCE study | Ziemssen, T.; Hobart, J.; FEYS, Peter ; Linnebank, M.; Goodman, A.; McNeill, M.; Zhong, J.; Mehta, L. | Journal Contribution | M |
